Will your cancer medicine cost less from 9 November? The India cancer medicine price revision 2026 may answer yes for many brands, but not all. The National Pharmaceutical Pricing Authority, or NPPA, has published revised maximum retail prices for 543 anti-cancer medicine brands and pack sizes, according to press reports on 28 October 2026, following the government’s decision on 17 October to cap trade margins at 30% on 137 non-scheduled anti-cancer medicines. This guide explains in plain language how the revision works, how patients and carers can check what applies to them and where the evidence is still thin.
Key takeaways: the India cancer medicine price revision 2026 for patients
- New maximum retail prices apply from 9 November 2026 for the 543 brands and pack sizes on the NPPA list.
- Reductions vary: reports mention cuts above 90% for some generics, while some originator brands are reported unchanged.
- The cap is on trade margins and applies to non-scheduled medicines; scheduled medicines have separate ceiling prices.
- Patients can check the MRP printed on the pack against the NPPA list and complain to the state drug controller if overcharged.
- We could not check the official schedule line by line, so examples are from press reports.
How the India cancer medicine price revision 2026 works
Every packaged medicine in India carries a maximum retail price, which a pharmacy cannot exceed. For many cancer drugs the MRP was set by the manufacturer and could be well above what distributors and retailers paid. The government decided to limit the trade margin to 30% of the MRP, excluding GST, for 137 non-scheduled anti-cancer medicines, and companies then submitted revised MRPs. The NPPA list, built on submissions up to 27 October, shows the new prices and will be updated as more come in. The authority’s site is the NPPA website.
Scheduled and non-scheduled medicines in the India cancer medicine price revision 2026
India’s price control system treats medicines in two groups. Scheduled medicines are those in the national list of essential medicines, whose ceiling prices are notified by the NPPA. Non-scheduled medicines are everything else, where the price can rise by a limited percentage a year but is not capped by a ceiling. This revision applies a margin cap to selected non-scheduled anti-cancer medicines. That matters because it explains why many newer or specialised cancer drugs were not covered by ceiling prices before. See also our report on the NPPA order on 137 cancer drugs.
How to check your medicine under the India cancer medicine price revision 2026
From 9 November, look at the price printed on the strip or vial and see whether the brand and pack size appear on the NPPA list. If the pharmacy asks for more than the printed MRP, ask for the bill and speak to the state drug controller. Because the list is company-submitted and still being updated, a brand not yet shown may be updated later. Ask your doctor or pharmacist before switching brands, since a different brand may differ in manufacturer, form or approval status. This is general information and not medical advice.
Why some prices fell more than others
A cut depends on how far the old MRP was above the trade price. Press examples show anastrozole tablets from RPG Life Sciences falling from Rs 695.76 to Rs 73 for ten tablets, and an azacitidine injection from Dr Reddy’s falling from Rs 6,337 to Rs 1,495.04. By our own arithmetic, those are cuts of about 89.5% and 76.4%. Where the old MRP was already close to the trade price, there would be little room to cut, which is one explanation offered for unchanged originator prices. We have not verified that explanation, and a drug-access group quoted in one report disputes how the cap was applied.
What critics say about the India cancer medicine price revision 2026
Not everyone is convinced. One report quotes the All India Drug Action Network arguing that the margin rule was never designed to ensure affordability of cancer treatment, that free volumes given through patient assistance programmes were excluded and so blunted cuts on patented drugs, and that MRPs are self-reported without verification. Supporters point to the scale of the cuts on many generics and biosimilars. The government has estimated savings of about Rs 2,500 crore a year from the broader initiative, according to reports, which we cannot verify.
Questions the India cancer medicine price revision 2026 leaves open
Several practical questions remain. What happens to stock already printed with old prices? Will hospitals that buy directly pass on lower prices? How will compliance be checked across thousands of retailers? Will the NPPA publish the schedule in a form patients can search easily? And will manufacturers respond by changing pack sizes or withdrawing brands? None of these is answered in the press coverage, and we do not speculate.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Cancer Therapeutics Market report values the global market at USD 193.7 billion in 2024 and USD 381.5 billion by 2033, a CAGR of 7.9% for 2025 to 2033. It says Asia Pacific is the fastest-growing region at more than 8.8%, targeted therapy had the largest treatment share and hospitals are the main end users. The page has a last-updated date of 2019 that conflicts with its 2024 base year, so use the figures as estimates. They are global and not a measure of Indian price changes. Related: Pharmaceutical coverage.
Timeline of the India cancer medicine price revision 2026
- 17 October 2026: government decision on a 30% trade margin cap for 137 medicines.
- 27 October 2026: cut-off for submissions in the list.
- 28 October 2026: NPPA list for 543 brands reported.
- 9 November 2026: revised MRPs take effect.
General background: why cancer drug prices are a policy issue
Cancer treatment can be long and expensive, and out-of-pocket payment is common in India. Policymakers have repeatedly looked at margins and prices, including an earlier cap on 42 drugs in 2019.
Our analysis of the India cancer medicine price revision 2026
In our assessment, the India cancer medicine price revision 2026 is a real but uneven relief. Patients using generic and biosimilar versions of drugs such as anastrozole, azacitidine, bevacizumab and dasatinib may see the largest differences, while those on unchanged brands will not. The proof will be in prices at the counter after 9 November.
What is not disclosed in the India cancer medicine price revision 2026
- The full schedule in a form we could verify line by line.
- Number of unchanged entries.
- Enforcement details.
Risks and caveats
Examples come from press reports and the list will change; the Department of Pharmaceuticals publishes related policy material at pharmaceuticals.gov.in. This article is general information and not medical advice.
What to watch next
- Updates to the NPPA list.
- Pharmacy compliance from 9 November.
- Industry or legal responses.
FAQ
Does the revision cover all cancer drugs?
No. It covers 543 brands and pack sizes under the margin cap.
Who do I complain to if charged more than MRP?
The state drug controller or the NPPA.
Should I change my medicine because of the new price?
Only on your doctor’s advice.
How we reported this: we relied on press reports of the NPPA list, the NPPA website and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 29 October 2026. This is news reporting and not advice.
